Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer

Treatment with EGFR kinase inhibitors improves progression-free survival of patients with EGFR-mutant lung cancer. However, all patients with initial response will eventually acquire resistance and die from tumor recurrence. We found that intermittent high-dose treatment with erlotinib induced apopt...

Descripción completa

Detalles Bibliográficos
Autores principales: Schöttle, Jakob, Chatterjee, Sampurna, Volz, Caroline, Siobal, Maike, Florin, Alexandra, Rokitta, Dennis, Hinze, Yvonne, Dietlein, Felix, Plenker, Dennis, König, Katharina, Albus, Kerstin, Heuckmann, Johannes M., Rauh, Daniel, Franz, Thomas, Neumaier, Bernd, Fuhr, Uwe, Heukamp, Lukas C., Ullrich, Roland T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770714/
https://www.ncbi.nlm.nih.gov/pubmed/26540572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770714/
https://www.ncbi.nlm.nih.gov/pubmed/26540572

Ejemplares similares